Format

Send to:

Choose Destination
See comment in PubMed Commons below
Oncotarget. 2014 Jul 30;5(14):5674-85.

Potentiation of tumor responses to DNA damaging therapy by the selective ATR inhibitor VX-970.

Author information

  • 1Vertex Pharmaceuticals Inc, Boston, MA, USA; These authors contributed equally to this work.
  • 2Vertex Pharmaceuticals Inc, Boston, MA, USA.
  • 3Vertex Pharmaceuticals (Europe) Ltd, Milton Park, Abingdon, Oxfordshire.

Abstract

Platinum-based DNA-damaging chemotherapy is standard-of-care for most patients with lung cancer but outcomes remain poor. This has been attributed, in part, to the highly effective repair network known as the DNA-damage response (DDR). ATR kinase is a critical regulator of this pathway, and its inhibition has been shown to sensitize some cancer, but not normal, cells in vitro to DNA damaging agents. However, there are limited in vivo proof-of-concept data for ATR inhibition. To address this we profiled VX-970, the first clinical ATR inhibitor, in a series of in vitro and in vivo lung cancer models and compared it with an inhibitor of the downstream kinase Chk1. VX-970 markedly sensitized a large proportion of a lung cancer cell line and primary tumor panel in vitro to multiple DNA damaging drugs with clear differences to Chk1 inhibition observed. In vivo VX-970 blocked ATR activity in tumors and dramatically enhanced the efficacy of cisplatin across a panel of patient derived primary lung xenografts. The combination led to complete tumor growth inhibition in three cisplatin-insensitive models and durable tumor regression in a cisplatin-sensitive model. These data provide a strong rationale for the clinical evaluation of VX-970 in lung cancer patients.

PMID:
25010037
[PubMed - in process]
PMCID:
PMC4170644
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Impact Journals, LLC Icon for PubMed Central
    Loading ...
    Write to the Help Desk